JP2023011549A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023011549A5 JP2023011549A5 JP2022143256A JP2022143256A JP2023011549A5 JP 2023011549 A5 JP2023011549 A5 JP 2023011549A5 JP 2022143256 A JP2022143256 A JP 2022143256A JP 2022143256 A JP2022143256 A JP 2022143256A JP 2023011549 A5 JP2023011549 A5 JP 2023011549A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- salt
- compound
- dose
- cell proliferative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 230000002062 proliferating effect Effects 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 206010069755 K-ras gene mutation Diseases 0.000 claims 3
- 230000003442 weekly effect Effects 0.000 claims 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- 102100039788 GTPase NRas Human genes 0.000 claims 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 229940127084 other anti-cancer agent Drugs 0.000 claims 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 2
- 229960005079 pemetrexed Drugs 0.000 claims 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 229960001467 bortezomib Drugs 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2024002690A JP2024056686A (ja) | 2017-11-16 | 2024-01-11 | クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018560956 | 2017-11-16 | ||
JP2018560956 | 2017-11-16 | ||
JP2020571576 | 2018-05-16 | ||
JP2020571576 | 2018-05-16 | ||
JP2018216023A JP7140645B2 (ja) | 2017-11-16 | 2018-11-16 | クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018216023A Division JP7140645B2 (ja) | 2017-11-16 | 2018-11-16 | クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024002690A Division JP2024056686A (ja) | 2017-11-16 | 2024-01-11 | クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2023011549A JP2023011549A (ja) | 2023-01-24 |
JP2023011549A5 true JP2023011549A5 (xx) | 2023-07-27 |
JP7420888B2 JP7420888B2 (ja) | 2024-01-26 |
Family
ID=76321132
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018216023A Active JP7140645B2 (ja) | 2017-11-16 | 2018-11-16 | クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬 |
JP2022143256A Active JP7420888B2 (ja) | 2017-11-16 | 2022-09-08 | クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬 |
JP2024002690A Pending JP2024056686A (ja) | 2017-11-16 | 2024-01-11 | クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018216023A Active JP7140645B2 (ja) | 2017-11-16 | 2018-11-16 | クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024002690A Pending JP2024056686A (ja) | 2017-11-16 | 2024-01-11 | クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬 |
Country Status (1)
Country | Link |
---|---|
JP (3) | JP7140645B2 (xx) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7140645B2 (ja) * | 2017-11-16 | 2022-09-21 | ジ インスティテュート オブ キャンサー リサーチ:ロイヤル キャンサー ホスピタル | クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
JP7140645B2 (ja) * | 2017-11-16 | 2022-09-21 | ジ インスティテュート オブ キャンサー リサーチ:ロイヤル キャンサー ホスピタル | クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬 |
-
2018
- 2018-11-16 JP JP2018216023A patent/JP7140645B2/ja active Active
-
2022
- 2022-09-08 JP JP2022143256A patent/JP7420888B2/ja active Active
-
2024
- 2024-01-11 JP JP2024002690A patent/JP2024056686A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2856646C (en) | Combination treatment of cancer | |
JP2019536805A5 (xx) | ||
CA2672000A1 (en) | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of lymphoma | |
JP2017537126A5 (xx) | ||
JP2018507243A5 (xx) | ||
JP2019516684A5 (xx) | ||
JP2006513184A5 (xx) | ||
JP2019521988A5 (xx) | ||
KR20180016350A (ko) | 구역과 구토를 치료하기 위한 아미설프리드 및 추가의 구토 방지제의 병용 | |
JP2021509395A5 (xx) | ||
JP2018503610A5 (xx) | ||
JP2021152002A5 (xx) | ||
JP2023011549A5 (xx) | ||
JP2019524888A5 (xx) | ||
JP2017508737A5 (xx) | ||
JP2024056686A (ja) | クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬 | |
JPWO2019241442A5 (xx) | ||
JP2010504307A5 (xx) | ||
JPWO2020118252A5 (xx) | ||
JPWO2019226761A5 (xx) | ||
JP2021091608A5 (xx) | ||
JP2020523317A5 (xx) | ||
TW201244732A (en) | Ezatiostat for treating multiple myeloma | |
EP3010508B1 (en) | Combination of ro5503781, capecitabine and oxaliplatin for cancer therapy | |
JP2012031141A (ja) | 骨髄異形性症候群を治療するための組成物および方法 |